Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Marc Botteman

University Name

United States

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

40%

Pharmacology

20%

Prostate Cancer

20%

Pharmacoeconomics

20%

Cancer Therapy

10%

Biologic Therapy

10%

Adjuvant Therapy

10%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles5

Corneal cross-linking versus conventional management for keratoconus: a lifetime economic model

Article Link

Year:

2021

Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States

Article Link

Year:

2021

Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment

Article Link

Year:

2020

Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy

Article Link

Year:

2020

Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis

Article Link

Year:

2020

Collaborators1

John Carter

UNITED STATES

How do I reach out?

Meet Kite AI